QuidelOrtho Corp. Hits New 52-Week Low at $10.86 Amid Ongoing Struggles

QuidelOrtho Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 10.86 as of April 23, 2026. This significant decline marks a stark contrast to its 52-week high of USD 38.99, reflecting a challenging year for the company with a staggering 72.67% drop in its stock price over the past year. The company's market capitalization stands at USD 1,202 million, and it has been grappling with consistent underperformance, having reported negative results for the last 12 consecutive quarters. Key financial metrics indicate a debt-equity ratio of 1.31, suggesting a higher reliance on debt, while the return on equity is reported at -7.95%. Additionally, the price-to-book ratio is notably low at 0.63, further emphasizing the stock's current valuation challenges. QuidelOrtho's performance has been significantly below the S&P 500, which has seen a positive return of 32.23% over the same period. The company's financial struggles, including a drastic decline in profits, highlight the difficulties it faces in the competitive biotechnology landscape.